April 21 (Reuters) - Valeant Pharmaceuticals International Inc
* Valeant’s patient access and pricing committee announces pricing for Siliq(brodalumab) as the lowest priced injectable biologic for moderate-to-severe plaque psoriasis
* Valeant - sales and marketing of Siliq are expected to commence in U.S. During second half of 2017
* Valeant - decided to list Siliq injection, at $3,500 per month
* Valeant - Siliq will also be included in company’s patient access program to further offer financial support and access to patients Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.